NASDAQ:MIRM

Mirum Pharmaceuticals Stock Insider Trading

Healthcare > Biotechnology

Buy MIRM

*Your capital is at risk

$119.04

-3.09 (-2.53%)

At Close: Jul 13, 2026

Mirum Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -54.28. In total, the insiders bought 645.53K and sold 166.81K MIRM shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-54.28
● Buy	645.53K shares
● Sell	166.81K shares
68% Buy Activity Weak Negative Correlation
Sell Signal Medium Confidence Jul 06, 2026 Analysis Breakdown: Strongly supported by a very low Insider Power Score of -54.28. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jul 06, 2026 Sell	Common Stock S-Sale	Peetz Christopher Chief Executive Officer	CEO / President	12 134 Value: $1.48M
Jul 06, 2026 Sell	Common Stock S-Sale	Peetz Christopher Chief Executive Officer	CEO / President	4 181 Value: $511.5K
Jul 06, 2026 Sell	Common Stock S-Sale	Peetz Christopher Chief Executive Officer	CEO / President	1 975 Value: $244.4K
Jul 06, 2026 Buy	Common Stock M-Exempt	Peetz Christopher Chief Executive Officer	CEO / President	20 000 Value: $58.7K
Jul 06, 2026 Sell	Common Stock S-Sale	Bjerkholt Eric Chief Financial Officer	C-Suite Officer	300 Value: $37.5K
Jul 06, 2026 Sell	Common Stock S-Sale	Bjerkholt Eric Chief Financial Officer	C-Suite Officer	528 Value: $65.4K
Jul 06, 2026 Sell	Common Stock S-Sale	Bjerkholt Eric Chief Financial Officer	C-Suite Officer	1 048 Value: $128.3K
Jul 06, 2026 Sell	Common Stock S-Sale	Bjerkholt Eric Chief Financial Officer	C-Suite Officer	3 124 Value: $380.1K
Jul 06, 2026 Buy	Employee Stock Option (right to buy) M-Exempt	Peetz Christopher Chief Executive Officer	CEO / President	20 000 Value: $58.7K
Jul 06, 2026 Sell	Common Stock S-Sale	Peetz Christopher Chief Executive Officer	CEO / President	1 710 Value: $213.4K
Jul 01, 2026 Sell	Common Stock S-Sale	Howe Jolanda SVP, Global Controller	Officer	2 721 Value: $326.5K
Jun 17, 2026 Sell	Common Stock S-Sale	Howe Jolanda SVP, Global Controller	Officer	2 594 Value: $264.5K
Jun 15, 2026 Buy	Deferred Stock Units A-Award	Brege Laura Director	Director	1 980 Value: $200.0K
Jun 15, 2026 Buy	Stock Option (right to buy) A-Award	Heron Patrick J Director	Director	3 772 Value: $381.0K
Jun 15, 2026 Buy	Deferred Stock Units A-Award	Heron Patrick J Director	Director	1 980 Value: $200.0K
Jun 15, 2026 Buy	Stock Option (right to buy) A-Award	Fischer Laurent Director	Director	3 772 Value: $381.0K
Jun 15, 2026 Buy	Stock Option (right to buy) A-Award	Grey Michael G Director	Director	3 772 Value: $381.0K
Jun 15, 2026 Buy	Stock Option (right to buy) A-Award	Walbert Timothy P Director	Director	3 772 Value: $381.0K
Jun 15, 2026 Buy	Restricted Stock Units A-Award	Walbert Timothy P Director	Director	1 980 Value: $200.0K
Jun 15, 2026 Buy	Stock Option (right to buy) A-Award	Cardon Lon Director	Director	3 772 Value: $381.0K
Jun 15, 2026 Buy	Restricted Stock Units A-Award	Cardon Lon Director	Director	1 980 Value: $200.0K
Jun 15, 2026 Buy	Stock Option (right to buy) A-Award	Fairey William Director	Director	3 772 Value: $381.0K
Jun 15, 2026 Buy	Deferred Stock Units A-Award	Fairey William Director	Director	1 980 Value: $200.0K
Jun 15, 2026 Buy	Restricted Stock Units A-Award	Ramasastry Saira Director	Director	1 980 Value: $200.0K
Jun 15, 2026 Buy	Stock Option (right to buy) A-Award	Ramasastry Saira Director	Director	3 772 Value: $381.0K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT MIRUM PHARMACEUTICALS, INC.

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment o...

Read Full Profile Here